
Title:
Valproate
Text:
Medication used for epilepsy, bipolar disorder and migraine


.mw-parser-output .infobox-subbox{padding:0;border:none;margin:-3px;width:auto;min-width:100%;font-size:100%;clear:none;float:none;background-color:transparent}.mw-parser-output .infobox-3cols-child{margin:auto}.mw-parser-output .infobox .navbar{font-size:100%}body.skin-minerva .mw-parser-output .infobox-header,body.skin-minerva .mw-parser-output .infobox-subheader,body.skin-minerva .mw-parser-output .infobox-above,body.skin-minerva .mw-parser-output .infobox-title,body.skin-minerva .mw-parser-output .infobox-image,body.skin-minerva .mw-parser-output .infobox-full-data,body.skin-minerva .mw-parser-output .infobox-below{text-align:center}ValproateINN: valproic acidClinical dataTrade namesDepakote, Epilim, Convulex, othersOther namesValproic acid; Sodium valproate (sodium); Valproate semisodium (semisodium); 2-Propylvaleric acidAHFS/Drugs.comMonographMedlinePlusa682412License data
US DailyMed: Valproic_acid
US FDA: Valproic%20acid
Pregnancycategory
AU: D

Routes ofadministrationBy mouth, intravenousATC codeN03AG01 (WHO) Legal statusLegal status
AU: S4 (Prescription only) 
CA:  ℞-only 
UK: POM (Prescription only) 
US: ℞-only 
Pharmacokinetic dataBioavailabilityRapid absorptionProtein binding80–90%[1]MetabolismLiver—glucuronide conjugation 30–50%, mitochondrial β-oxidation over 40%Elimination half-life9–16 hours[1]ExcretionUrine (30–50%)[1]Identifiers
IUPAC name
2-propylpentanoic acid
CAS Number99-66-1 YPubChem CID3121IUPHAR/BPS7009DrugBankDB00313 YChemSpider3009 YUNII614OI1Z5WIKEGGD00399 YChEBICHEBI:39867 YChEMBLChEMBL109 YNIAID ChemDB057177CompTox Dashboard (EPA)DTXSID6023733 ECHA InfoCard100.002.525 Chemical and physical dataFormulaC8H16O2Molar mass144.214 g·mol−13D model (JSmol)Interactive image
SMILES
O=C(O)C(CCC)CCC

InChI
InChI=1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10) YKey:NIJJYAXOARWZEE-UHFFFAOYSA-N Y
.mw-parser-output .nobold{font-weight:normal}  (verify)
Valproate (VPA) and its valproic acid, sodium valproate, and valproate semisodium forms are medications primarily used to treat epilepsy and bipolar disorder and prevent migraine headaches.[2] They are useful for the prevention of seizures in those with absence seizures, partial seizures, and generalized seizures.[2] They can be given intravenously or by mouth, and the tablet forms exist in both long- and short-acting formulations.[2]
Common side effects of valproate include nausea, vomiting, sleepiness, and dry mouth.[2] Serious side effects can include liver failure, and regular monitoring of liver function tests is therefore recommended.[2] Other serious risks include pancreatitis and an increased suicide risk.[2] Valproate is known to cause serious abnormalities in babies if taken during pregnancy,[2][3] and as such it is not typically recommended for women of childbearing age who have migraines.[2]
Valproate's precise mechanism of action is unclear.[2][4] Proposed mechanisms include affecting GABA levels, blocking voltage-gated sodium channels, and inhibiting histone deacetylases.[5][6] Valproic acid is a branched short-chain fatty acid (SCFA) made from valeric acid.[5]
Valproate was first made in 1881 and came into medical use in 1962.[7] It is on the World Health Organization's List of Essential Medicines[8] and is available as a generic medication.[2] In 2019, it was the 114th most commonly prescribed medication in the United States, with more than 5 million prescriptions.[9][10]

.mw-parser-output .toclimit-2 .toclevel-1 ul,.mw-parser-output .toclimit-3 .toclevel-2 ul,.mw-parser-output .toclimit-4 .toclevel-3 ul,.mw-parser-output .toclimit-5 .toclevel-4 ul,.mw-parser-output .toclimit-6 .toclevel-5 ul,.mw-parser-output .toclimit-7 .toclevel-6 ul{display:none}Contents

1 Terminology
2 Medical uses

2.1 Epilepsy
2.2 Mental illness

2.2.1 Bipolar disorder
2.2.2 Schizophrenia
2.2.3 Dopamine dysregulation syndrome


2.3 Migraines
2.4 Other


3 Contraindications
4 Adverse effects

4.1 Pregnancy
4.2 Elderly


5 Overdose and toxicity
6 Interactions
7 Pharmacology

7.1 Pharmacodynamics

7.1.1 Endocrine actions


7.2 Pharmacokinetics


8 Chemistry
9 History
10 Society and culture

10.1 Approval status
10.2 Off-label uses
10.3 Formulations

10.3.1 Brand names of valproic acid
10.3.2 Brand names of sodium valproate

10.3.2.1 Portugal
10.3.2.2 United States
10.3.2.3 Australia
10.3.2.4 New Zealand
10.3.2.5 UK

10.3.2.5.1 UK only


10.3.2.6 Germany, Switzerland, Norway, Finland, Sweden
10.3.2.7 South Africa
10.3.2.8 Malaysia
10.3.2.9 Romania
10.3.2.10 Canada
10.3.2.11 Japan
10.3.2.12 Europe
10.3.2.13 Taiwan
10.3.2.14 Iran
10.3.2.15 Israel
10.3.2.16 India, Russia and CIS countries


10.3.3 Brand names of valproate semisodium




11 References
12 External links



Terminology[edit]
Valproic acid (VPA) is an organic weak acid. The conjugate base is valproate. The sodium salt of the acid is sodium valproate and a coordination complex of the two is known as valproate semisodium.[11]

Medical uses[edit]
It is used primarily to treat epilepsy and bipolar disorder. It is also used to prevent migraine headaches.[12]

Epilepsy[edit]
Valproate has a broad spectrum of anticonvulsant activity, although it is primarily used as a first-line treatment for tonic–clonic seizures, absence seizures and myoclonic seizures and as a second-line treatment for partial seizures and infantile spasms.[12][13] It has also been successfully given intravenously to treat status epilepticus.[14][15]

Mental illness[edit]
Bipolar disorder[edit]
Valproate products are also used to treat manic or mixed episodes of bipolar disorder.[16][17]

Schizophrenia[edit]
A 2016 systematic review compared the efficacy of valproate as an add-on for people with schizophrenia:[18]




There is limited evidence that adding valproate to antipsychotics may be effective for overall response and also for specific symptoms, especially in terms of excitement and aggression. Valproate was associated with a number of adverse events among which sedation and dizziness appeared more frequently than in the control groups.[18]






Outcome

Findings in words

Findings in numbers

Quality of evidence


Global outcome


Clinically significant response
When added to antipsychotic drugs valproate probably increases the chance of improvement. Data are based on moderate quality evidence.

RR 1.31 (1.16 to 1.47)
Moderate


Leaving the study early for any reason
Valproate in combination with antipsychotics may slightly reduce the chance of leaving the study early, but the difference between the two treatments is not clear. Data supporting this finding are based on moderate quality evidence.

RR 0.76 (0.47 to 1.24)
Moderate


Use of additional medication for sedation
The combination of valproate and antipsychotic drugs may increase the chance of being given additional sedating medication, but, at present it is not possible to be confident about the difference between the two treatments and data supporting this finding are very limited.

RR 3.65 (0.11 to 122.31)
Very low


Mental state


Average score (PANSS total, high = poor)
On average, people receiving the valproate combination scored lower (better) than people treated with antipsychotics in combination with placebo or antipsychotic drugs alone. There was a clear difference between the groups, but the meaning of this in day-to-day care is unclear.
MD 5.85 lower (7.8 lower to 3.91 lower)
Moderate


Adverse events


Abnormal liver function (blood test changes)*
Adding valproate to antipsychotic drug treatment does not clearly cause liver problems. Data supporting this finding are based on moderate quality evidence.

RR 1.26 (0.72 to 2.22)
Moderate


Nausea
Adding valproate to antipsychotic drugs probably causes little or no increase to the chance of feeling sick, but the difference between the two treatments is not clear. Data supporting this finding are based on moderate quality evidence.

RR 1.22 (0.80 to 1.86)
Moderate


Missing outcomes and notes



Quality of life outcomes were not reported in the included studies. *Increase in alanine transaminase/gamma-glutamyl transpeptidase





Dopamine dysregulation syndrome[edit]
Based upon five case reports, valproic acid may have efficacy in controlling the symptoms of the dopamine dysregulation syndrome that arise from the treatment of Parkinson's disease with levodopa.[19][20][21]

Migraines[edit]
Valproate is also used to prevent migraine headaches. Because this medication can be potentially harmful to the fetus, valproate should be considered for those able to become pregnant only after the risks have been discussed.[22]

Other[edit]
The medication has been tested in the treatment of AIDS and cancer, owing to its histone-deacetylase-inhibiting effects.[23]

Contraindications[edit]
Contraindications include:

Pre-existing acute or chronic liver dysfunction or family history of severe liver inflammation (hepatitis), particularly medicine related.[24]
Known hypersensitivity to valproate or any of the ingredients used in the preparation[24]
Urea cycle disorders[24]
Hepatic porphyria[24]
Hepatotoxicity[24]
Mitochondrial disease[24]
Pancreatitis[24]
Porphyria[25]
Adverse effects[edit]
.mw-parser-output .hatnote{font-style:italic}.mw-parser-output div.hatnote{padding-left:1.6em;margin-bottom:0.5em}.mw-parser-output .hatnote i{font-style:normal}.mw-parser-output .hatnote+link+.hatnote{margin-top:-0.5em}See also: List of adverse effects of valproic acid and List of adverse effects of valproate semisodium
.mw-parser-output .div-col{margin-top:0.3em;column-width:30em}.mw-parser-output .div-col-small{font-size:90%}.mw-parser-output .div-col-rules{column-rule:1px solid #aaa}.mw-parser-output .div-col dl,.mw-parser-output .div-col ol,.mw-parser-output .div-col ul{margin-top:0}.mw-parser-output .div-col li,.mw-parser-output .div-col dd{page-break-inside:avoid;break-inside:avoid-column}
Most common adverse effects include:[22]

Nausea (22%)
Drowsiness (19%)
Dizziness (12%)
Vomiting (12%)
Weakness (10%)
Serious adverse effects include:[22]

Bleeding
Low blood platelets
Encephalopathy
Suicidal behavior and thoughts
Low body temperature

Valproic acid has a black box warning for hepatotoxicity, pancreatitis, and fetal abnormalities.[22]
It is worthy of mentioning that some adverse effects related to valproic acid may be dose-dependent such as pancytopenia.[26]
There is evidence that valproic acid may cause premature growth plate ossification in children and adolescents, resulting in decreased height.[27][28][29][30] Valproic acid can also cause mydriasis, a dilation of the pupils.[31] There is evidence that shows valproic acid may increase the chance of polycystic ovary syndrome (PCOS) in women with epilepsy or bipolar disorder. Studies have shown this risk of PCOS is higher in women with epilepsy compared to those with bipolar disorder.[32] Weight gain is also possible.[33]

Pregnancy[edit]
Valproate causes birth defects;[34] exposure during pregnancy is associated with about three times as many major abnormalities as usual, mainly spina bifida with the risks being related to the strength of medication used and use of more than one drug.[35][36] More rarely, with several other defects, including a "valproate syndrome".[37] Characteristics of this valproate syndrome include facial features that tend to evolve with age, including a triangle-shaped forehead, tall forehead with bifrontal narrowing, epicanthic folds, medial deficiency of eyebrows, flat nasal bridge, broad nasal root, anteverted nares, shallow philtrum, long upper lip and thin vermillion borders, thick lower lip and small downturned mouth.[38] While developmental delay is usually associated with altered physical characteristics (dysmorphic features), this is not always the case.[39]
Children of mothers taking valproate during pregnancy are at risk for lower IQs.[40][41][42] Maternal valproate use during pregnancy increased the probability of autism in the offspring compared to mothers not taking valproate from 1.5% to 4.4%.[43] A 2005 study found rates of autism among children exposed to sodium valproate before birth in the cohort studied were 8.9%.[44] The normal incidence for autism in the general population is estimated at less than one percent.[45] A 2009 study found that the 3-year-old children of pregnant women taking valproate had an IQ nine points lower than that of a well-matched control group. However, further research in older children and adults is needed.[46][47][48]
Sodium valproate has been associated with paroxysmal tonic upgaze of childhood, also known as Ouvrier–Billson syndrome, from childhood or fetal exposure. This condition resolved after discontinuing valproate therapy.[49][50]
Women who intend to become pregnant should switch to a different medication if possible or decrease their dose of valproate.[51] Women who become pregnant while taking valproate should be warned that it causes birth defects and cognitive impairment in the newborn, especially at high doses (although valproate is sometimes the only drug that can control seizures, and seizures in pregnancy could have worse outcomes for the fetus than exposure to valproate). Studies have shown that taking folic acid supplements can reduce the risk of congenital neural tube defects.[22] The use of valproate for migraine or bipolar disorder during pregnancy is contraindicated in the European Union, and the medicines are not recommended for epilepsy during pregnancy unless there is no other effective treatment available.[52]

Elderly[edit]
Valproate in elderly people with dementia caused increased sleepiness. More people stopped the medication for this reason. Additional side effects of weight loss and decreased food intake were also associated with one-half of people who become sleepy.[22]

Overdose and toxicity[edit]

Therapeutic range of valproic acid


Form

Lower limit

Upper limit

Unit


Total (including protein bound)

50[53]
125[53]
µg/mL or mg/l


350[54]
700[54]
μmol/L


Free

6[53]
22[53]
µg/mL or mg/l


35[54]
70[54]
μmol/L

Excessive amounts of valproic acid can result in sleepiness, tremor, stupor, respiratory depression, coma, metabolic acidosis, and death.[55] In general, serum or plasma valproic acid concentrations are in a range of 20–100 mg/l during controlled therapy, but may reach 150–1500 mg/l following acute poisoning. Monitoring of the serum level is often accomplished using commercial immunoassay techniques, although some laboratories employ gas or liquid chromatography.[56]
In contrast to other antiepileptic drugs, at present there is little favorable evidence for salivary therapeutic drug monitoring. Salivary levels of valproic acid correlate poorly with serum levels, partly due to valproate's weak acid property (pKa of 4.9).[57]
In severe intoxication, hemoperfusion or hemofiltration can be an effective means of hastening elimination of the drug from the body.[58][59] Supportive therapy should be given to all patients experiencing an overdose and urine output should be monitored.[22] Supplemental L-carnitine is indicated in patients having an acute overdose[60][61] and also prophylactically[60] in high risk patients. Acetyl-L-carnitine lowers hyperammonemia less markedly[62] than L-carnitine. 

Interactions[edit]
Valproate inhibits CYP2C9, glucuronyl transferase, and epoxide hydrolase and is highly protein bound and hence may interact with drugs that are substrates for any of these enzymes or are highly protein bound themselves.[24] It may also potentiate the CNS depressant effects of alcohol.[24] It should not be given in conjunction with other antiepileptics due to the potential for reduced clearance of other antiepileptics (including carbamazepine, lamotrigine, phenytoin and phenobarbitone) and itself.[24] It may also interact with:[22][24][63]

Aspirin: may increase valproate concentrations. May also interfere with valproate's metabolism.
Benzodiazepines: may cause CNS depression and there are possible pharmacokinetic interactions.
Carbapenem antibiotics: reduce valproate levels, potentially leading to seizures.
Cimetidine: inhibits valproate's metabolism in the liver, leading to increased valproate concentrations.
Erythromycin: inhibits valproate's metabolism in the liver, leading to increased valproate concentrations.
Ethosuximide: valproate may increase ethosuximide concentrations and lead to toxicity.
Felbamate: may increase plasma concentrations of valproate.
Mefloquine: may increase valproate metabolism combined with the direct epileptogenic effects of mefloquine.
Oral contraceptives: may reduce plasma concentrations of valproate.
Primidone: may accelerate metabolism of valproate, leading to a decline of serum levels and potential breakthrough seizure.
Rifampicin: increases the clearance of valproate, leading to decreased valproate concentrations
Warfarin: valproate may increase free warfarin concentration and prolong bleeding time.
Zidovudine: valproate may increase zidovudine serum concentration and lead to toxicity.
Pharmacology[edit]
Pharmacodynamics[edit]
Although the mechanism of action of valproate is not fully understood,[24] traditionally, its anticonvulsant effect has been attributed to the blockade of voltage-gated sodium channels and increased brain levels of gamma-aminobutyric acid (GABA).[24] The GABAergic effect is also believed to contribute towards the anti-manic properties of valproate.[24] In animals, sodium valproate raises cerebral and cerebellar levels of the inhibitory synaptic neurotransmitter, GABA, possibly by inhibiting GABA degradative enzymes, such as GABA transaminase, succinate-semialdehyde dehydrogenase and by inhibiting the re-uptake of GABA by neuronal cells.[24]
Prevention of neurotransmitter-induced hyperexcitability of nerve cells, via Kv7.2 channel and AKAP5, may also contribute to its mechanism.[64] Also, it has been shown to protect against a seizure-induced reduction in phosphatidylinositol (3,4,5)-trisphosphate (PIP3) as a potential therapeutic mechanism.[65]
It also has histone-deacetylase-inhibiting effects. The inhibition of histone deacetylase, by promoting more transcriptionally active chromatin structures, likely presents the epigenetic mechanism for regulation of many of the neuroprotective effects attributed to valproic acid. Intermediate molecules mediating these effects include VEGF, BDNF, and GDNF.[66][67]

Endocrine actions[edit]
Valproic acid has been found to be an antagonist of the androgen and progesterone receptors, and hence as a nonsteroidal antiandrogen and antiprogestogen, at concentrations much lower than therapeutic serum levels.[68] In addition, the drug has been identified as a potent aromatase inhibitor, and suppresses estrogen concentrations.[69] These actions are likely to be involved in the reproductive endocrine disturbances seen with valproic acid treatment.[68][69]
Valproic acid has been found to directly stimulate androgen biosynthesis in the gonads via inhibition of histone deacetylases and has been associated with hyperandrogenism in women and increased 4-androstenedione levels in men.[70][71] High rates of polycystic ovary syndrome and menstrual disorders have also been observed in women treated with valproic acid.[71]

Pharmacokinetics[edit]
  Some metabolites of valproic acid. Glucuronidation and β-oxidation are the main metabolic pathways; ω-oxidation metabolites are considered hepatotoxic.[72][73] Details see text.
Taken by mouth, valproate is rapidly and virtually completely absorbed from the gut.[72] When in the bloodstream, 80–90% of the substance are bound to plasma proteins, mainly albumin. Protein binding is saturable: it decreases with increasing valproate concentration, low albumin concentrations, the patient's age, additional use of other drugs such as aspirin, as well as liver and kidney impairment.[74][75] Concentrations in the cerebrospinal fluid and in breast milk are 1 to 10% of blood plasma concentrations.[72]
The vast majority of valproate metabolism occurs in the liver.[76] Valproate is known to be metabolized by the cytochrome P450 enzymes CYP2A6, CYP2B6, CYP2C9, and CYP3A5.[76] It is also known to be metabolized by the UDP-glucuronosyltransferase enzymes UGT1A3, UGT1A4, UGT1A6, UGT1A8, UGT1A9, UGT1A10, UGT2B7, and UGT2B15.[76]  Some of the known metabolites of valproate by these enzymes and uncharacterized enzymes include (see image):[76]

via glucuronidation (30–50%): valproic acid β-O-glucuronide
via beta oxidation (>40%): 2E-ene-valproic acid, 2Z-ene-valproic acid, 3-hydroxyvalproic acid, 3-oxovalproic acid
via omega oxidation: 5-hydroxyvalproic acid, 2-propyl-glutaric acid
some others: 3E-ene-valproic acid, 3Z-ene-valproic acid, 4-ene-valproic acid, 4-hydroxyvalproic acid
All in all, over 20 metabolites are known.[72]
In adult patients taking valproate alone, 30–50% of an administered dose is excreted in urine as the glucuronide conjugate.[76]  The other major pathway in the metabolism of valproate is mitochondrial beta oxidation, which typically accounts for over 40% of an administered dose.[76] Typically, less than 20% of an administered dose is eliminated by other oxidative mechanisms.[76] Less than 3% of an administered dose of valproate is excreted unchanged (i.e., as valproate) in urine.[76] Only a small amount is excreted via the faeces.[72] Elimination half-life is 16±3 hours and can decrease to 4–9 hours when combined with enzyme inducers.[72][75]

Chemistry[edit]
Valproic acid is a branched short-chain fatty acid and the 2-n-propyl derivative of valeric acid.[5]

History[edit]
Valproic acid was first synthesized in 1882 by Beverly S. Burton as an analogue of valeric acid, found naturally in valerian.[77] Valproic acid is a carboxylic acid, a clear liquid at room temperature. For many decades, its only use was in laboratories as a "metabolically inert" solvent for organic compounds. In 1962, the French researcher Pierre Eymard serendipitously discovered the anticonvulsant properties of valproic acid while using it as a vehicle for a number of other compounds that were being screened for antiseizure activity. He found it prevented pentylenetetrazol-induced convulsions in laboratory rats.[78] It was approved as an antiepileptic drug in 1967 in France and has become the most widely prescribed antiepileptic drug worldwide.[79] Valproic acid has also been used for migraine prophylaxis and bipolar disorder.[80]

Society and culture[edit]
Valproate is available as a generic medication.[2]

Approval status[edit]



Indications

FDA-labelled indication?[1]

TGA-labelled indication?[12]

MHRA-labelled indication?[81]

Literature support


Epilepsy
Yes
Yes
Yes
Limited (depends on the seizure type; it can help with certain kinds of seizures: drug-resistant epilepsy, partial and absence seizures, can be used against glioblastoma and other tumors both to improve survival and treat seizures, and against tonic–clonic seizures and status epilepticus).[82][83][84][85]


Bipolar mania
Yes
Yes
Yes
Limited.[86]


Bipolar depression
No
No
No
Moderate.[87]


Bipolar maintenance
No
No
No
Limited.[88]


Migraine prophylaxis
Yes
Yes (accepted)
No
Limited.


Acute migraine management
No
No
No
Only negative results.[89]


Schizophrenia
No
No
No
Weak evidence.[90]


Agitation in dementia
No
No
No
Weak evidence. Not recommended for agitation in people with dementia.[91] Increased rate of adverse effects, including a risk of serious adverse effects.[91]


Fragile X syndrome
Yes (orphan)
No
No
Limited.[67]


Familial adenomatous polyposis
Yes (orphan)
No
No
Limited.


Chronic pain & fibromyalgia
No
No
No
Limited.[92]


Alcohol hallucinosis
No
No
No
One randomised double-blind placebo-controlled trial.[93]


Intractable hiccups
No
No
No
Limited, five case reports support its efficacy, however.[94]


Non-epileptic myoclonus
No
No
No
Limited, three case reports support its efficacy, however.[95]


Cluster headaches
No
No
No
Limited, two case reports support its efficacy.[96]


West syndrome
No
No
No
A prospective clinical trial supported its efficacy in treating infantile spasms.[97]


HIV infection eradication
No
No
No
Double-blind placebo-controlled trials have been negative.[98][99][100]


Myelodysplastic syndrome
No
No
No
Several clinical trials have confirmed its efficacy as a monotherapy,[101] as an adjunct to tretinoin[101] and as an adjunct to hydralazine.[102]


Acute myeloid leukaemia
No
No
No
Two clinical trials have confirmed its efficacy in this indication as both a monotherapy and as an adjunct to tretinoin.[103][104][105]


Cervical cancer
No
No
No
One clinical trial supports its use here.[106]


Malignant melanoma
No
No
No
One phase II study has seemed to discount its efficacy.[107]


Breast cancer
No
No
No
A phase II study has supported its efficacy.[108]


Impulse control disorder
No
No
No
Limited.[109][110]

Off-label uses[edit]
In 2012, pharmaceutical company Abbott paid $1.6 billion in fines to US federal and state governments for illegal promotion of off-label uses for Depakote, including the sedation of elderly nursing home residents.[111][112]
Some studies have suggested that valproate may reopen the critical period for learning absolute pitch and possibly other skills such as language.[113][114]

Formulations[edit]
Sodium valproateClinical dataOther namesvalproate sodium (USAN US)License data
US DailyMed: Valproate_sodium
Identifiers
IUPAC name
sodium 2-propylpentanoate
CAS Number1069-66-5 YPubChem CID16760703DrugBankDBSALT001257 YChemSpider13428 YUNII5VOM6GYJ0DKEGGD00710 YChEBICHEBI:9925 YChEMBLChEMBL433 YCompTox Dashboard (EPA)DTXSID6023733 ECHA InfoCard100.002.525 Chemical and physical dataFormulaC8H15NaO2Molar mass166.196 g·mol−13D model (JSmol)Interactive image
SMILES
CCCC(CCC)C(=O)[O-].[Na+]

InChI
InChI=1S/C8H16O2.Na/c1-3-5-7(6-4-2)8(9)10;/h7H,3-6H2,1-2H3,(H,9,10);/q;+1/p-1 YKey:AEQFSUDEHCCHBT-UHFFFAOYSA-M Y
  (verify)
Valproate semisodiumClinical dataTrade namesDepakote, othersOther namessemisodium valproate, divalproex sodium (USAN US)License data
US DailyMed: Divalproex_sodium
Identifiers
IUPAC name
sodium;2-propylpentanoate;2-propylpentanoic acid
CAS Number76584-70-8 YPubChem CID23663956DrugBankDBSALT000185 YChemSpider48337 YUNII644VL95AO6KEGGD00304 YChEBICHEBI:4667 YChEMBLChEMBL2105613 YCompTox Dashboard (EPA)DTXSID6023733 ECHA InfoCard100.002.525 Chemical and physical dataFormulaC16H31NaO4Molar mass310.410 g·mol−13D model (JSmol)Interactive image
SMILES
CCCC(CCC)C(=O)O.CCCC(CCC)C(=O)[O-].[Na+]

InChI
InChI=1S/2C8H16O2.Na/c2*1-3-5-7(6-4-2)8(9)10;/h2*7H,3-6H2,1-2H3,(H,9,10);/q;;+1/p-1 YKey:MSRILKIQRXUYCT-UHFFFAOYSA-M Y

Valproate exists in two main molecular variants: sodium valproate and valproic acid without sodium (often implied by simply valproate). A mixture between these two is termed semisodium valproate. It is unclear whether there is any difference in efficacy between these variants, except from the fact that about 10% more mass of sodium valproate is needed than valproic acid without sodium to compensate for the sodium itself.[115]

Brand names of valproic acid[edit]
Branded products include:


Absenor (Orion Corporation Finland)
Convulex (G.L. Pharma GmbH Austria)
Depakene (Abbott Laboratories in US and Canada)[116]
Depakine (Sanofi Aventis France)
Depakine (Sanofi Synthelabo Romania)
Depalept (Sanofi Aventis Israel)
Deprakine (Sanofi Aventis Finland)
Encorate (Sun Pharmaceuticals India)
Epival (Abbott Laboratories US and Canada)
Epilim (Sanofi Synthelabo Australia and South Africa)
Stavzor (Noven Pharmaceuticals Inc.)
Valcote (Abbott Laboratories Argentina)
Valpakine (Sanofi Aventis Brazil)
Orfiril (Desitin Arzneimittel GmbH Norway)

Brand names of sodium valproate[edit]
Portugal[edit]
Tablets – Diplexil-R by Bial.
United States[edit]
Intravenous injection – Depacon by Abbott Laboratories.
Syrup – Depakene by Abbott Laboratories. (Note Depakene capsules are valproic acid).
Depakote tablets are a mixture of sodium valproate and valproic acid.
Tablets – Eliaxim by Bial.
Australia[edit]
Epilim Crushable Tablets Sanofi[117]
Epilim Sugar Free Liquid Sanofi[117]
Epilim Syrup Sanofi[117]
Epilim Tablets Sanofi[117]
Sodium Valproate Sandoz Tablets Sanofi
Valpro Tablets Alphapharm
Valproate Winthrop Tablets Sanofi
Valprease tablets Sigma
New Zealand[edit]
Epilim by Sanofi-Aventis
All the above formulations are Pharmac-subsidised.[118]

UK[edit]
Depakote Tablets (as in USA)
Tablets – Orlept by Wockhardt and Epilim by Sanofi
Oral solution – Orlept Sugar Free by Wockhardt and Epilim by Sanofi
Syrup – Epilim by Sanofi-Aventis
Intravenous injection – Epilim Intravenous by Sanofi
Extended release tablets – Epilim Chrono by Sanofi is a combination of sodium valproate and valproic acid in a 2.3:1 ratio.
Enteric-coated tablets – Epilim EC200 by Sanofi is a 200-mg sodium valproate enteric-coated tablet.
UK only[edit]
Capsules – Episenta prolonged release by Beacon
Sachets – Episenta prolonged release by Beacon
Intravenous solution for injection – Episenta solution for injection by Beacon
Germany, Switzerland, Norway, Finland, Sweden[edit]
Tablets – Orfiril by Desitin Pharmaceuticals
Intravenous injection – Orfiril IV by Desitin Pharmaceuticals
South Africa[edit]
Syrup – Convulex by Byk Madaus[119]
Tablets – Epilim by Sanofi-synthelabo
Malaysia[edit]
Tablets – Epilim by Sanofi-Aventis
Romania[edit]
Companies are SANOFI-AVENTIS FRANCE, GEROT PHARMAZEUTIKA GMBH and DESITIN ARZNEIMITTEL GMBH
Types are Syrup, Extended release mini tablets, Gastric resistant coated tablets, Gastric resistant soft capsules, Extended release capsules, Extended release tablets and Extended release coated tablets
Canada[edit]
Intravenous injection – Epival or Epiject by Abbott Laboratories.
Syrup – Depakene by Abbott Laboratories its generic formulations include Apo-Valproic and ratio-Valproic.
Japan[edit]
Tablets – Depakene by Kyowa Hakko Kirin
Extended release tablets – Depakene-R by Kyowa Hakko Kogyo and Selenica-R by Kowa
Syrup – Depakene by Kyowa Hakko Kogyo
Europe[edit]
In much of Europe, Dépakine and Depakine Chrono (tablets) are equivalent to Epilim and Epilim Chrono above.

Taiwan[edit]
Tablets (white round tablet) – Depakine (Chinese: 帝拔癲; pinyin: di-ba-dian) by Sanofi Winthrop Industrie (France)
Iran[edit]
Tablets – Epival 200 (enteric coated tablet) and Epival 500 (extended release tablet) by Iran Najo
Slow release tablets – Depakine Chrono by Sanofi Winthrop Industrie (France)
Israel[edit]
Depalept and Depalept Chrono (extended release tablets) are equivalent to Epilim and Epilim Chrono above. Manufactured and distributed by Sanofi-Aventis.

India, Russia and CIS countries[edit]
Valparin Chrono by Sanofi India
Valprol CR by Intas Pharmaceutical (India)
Encorate Chrono by Sun Pharmaceutical (India)
Serven Chrono by Leeven APL Biotech (India)
Brand names of valproate semisodium[edit]
Brazil – Depakote by Abbott Laboratories and Torval CR by Torrent do Brasil
Canada – Epival by Abbott Laboratories
Mexico – Epival and Epival ER (extended release) by Abbott Laboratories
United Kingdom – Depakote (for psychiatric conditions) and Epilim (for epilepsy) by Sanofi-Aventis and generics
United States – Depakote and Depakote ER (extended release) by Abbott Laboratories and generics[22]
India – Valance and Valance OD by Abbott Healthcare Pvt Ltd, Divalid ER by Linux laboratories Pvt Ltd, Valex ER by Sigmund Promedica, Dicorate by Sun Pharma
Germany – Ergenyl Chrono by Sanofi-Aventis and generics
Chile – Valcote and Valcote ER by Abbott Laboratories
France and other European countries — Depakote
Peru – Divalprax by AC Farma Laboratories
China – Diprate OD
References[edit]
.mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman}

^ a b c d .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:#d33}.mw-parser-output .cs1-visible-error{color:#d33}.mw-parser-output .cs1-maint{display:none;color:#3a3;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}"Depakene, Stavzor (valproic acid) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 21 February 2014. Retrieved 13 February 2014.

^ a b c d e f g h i j k "Valproic Acid". The American Society of Health-System Pharmacists. Archived from the original on 31 July 2017. Retrieved 23 October 2015.

^ "Valproate banned without the pregnancy prevention programme". GOV.UK. Retrieved 26 April 2018.

^ Owens MJ, Nemeroff CB (2003). "Pharmacology of valproate". Psychopharmacol Bull. 37 Suppl 2: 17–24. PMID 14624230.

^ a b c Ghodke-Puranik Y, Thorn CF, Lamba JK, Leeder JS, Song W, Birnbaum AK, Altman RB, Klein TE (April 2013). "Valproic acid pathway: pharmacokinetics and pharmacodynamics". Pharmacogenet. Genomics. 23 (4): 236–241. doi:10.1097/FPC.0b013e32835ea0b2. PMC 3696515. PMID 23407051.

^ "Valproic acid". DrugBank. University of Alberta. 29 July 2017. Archived from the original on 31 July 2017. Retrieved 30 July 2017.

^ Scott, D.F. (1993). The history of epileptic therapy : an account of how medication was developed (1. publ. ed.). Carnforth u.a.: Parthenon Publ. Group. p. 131. ISBN 9781850703914.

^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

^ "The Top 300 of 2019". ClinCalc. Retrieved 16 October 2021.

^ "Valproate - Drug Usage Statistics". ClinCalc. Retrieved 16 October 2021. 

^ Brayfield, Alison (ed.). Martindale: The Complete Drug Reference. London: Pharmaceutical Press. Retrieved 3 March 2018.

^ a b c Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.

^ Löscher W (2002). "Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy". CNS Drugs. 16 (10): 669–694. doi:10.2165/00023210-200216100-00003. PMID 12269861. S2CID 67999301.

^ Olsen KB, Taubøll E, Gjerstad L (2007). "Valproate is an effective, well-tolerated drug for treatment of status epilepticus/serial attacks in adults". Acta Neurol. Scand. Suppl. 187: 51–4. doi:10.1111/j.1600-0404.2007.00847.x. PMID 17419829. S2CID 11159645.

^ Kwan SY (2010). "The role of intravenous valproate in convulsive status epilepticus in the future" (PDF). Acta Neurol Taiwan. 19 (2): 78–81. PMID 20830628.[permanent dead link]

^ "Valproate Information". Fda.gov. Archived from the original on 3 May 2015. Retrieved 24 April 2015.

^ Jochim, Janina; Rifkin-Zybutz, Raphael; Geddes, John; Cipriani, Andrea (7 October 2019). "Valproate for acute mania". Cochrane Database of Systematic Reviews. 10: CD004052. doi:10.1002/14651858.CD004052.pub2. PMC 6797024. PMID 31621892.

^ a b Wang, Y; Xia, J; Helfer, B (2016). "Valproate for schizophrenia". Cochrane Database of Systematic Reviews. 2016 (11): CD004028.pub4. doi:10.1002/14651858.CD004028.pub4. PMC 6734130. PMID 27884042. Archived from the original on 29 July 2017. Retrieved 27 July 2017.

^ Pirritano D, Plastino M, Bosco D, Gallelli L, Siniscalchi A, De Sarro G (2014). "Gambling disorder during dopamine replacement treatment in Parkinson's disease: a comprehensive review". Biomed Res Int. 2014: 1–9. doi:10.1155/2014/728038. PMC 4119624. PMID 25114917.

^ Connolly B, Fox SH (2014). "Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease". Neurotherapeutics. 11 (1): 78–91. doi:10.1007/s13311-013-0238-x. PMC 3899484. PMID 24288035.

^ Averbeck BB, O'Sullivan SS, Djamshidian A (2014). "Impulsive and compulsive behaviors in Parkinson's disease". Annu Rev Clin Psychol. 10: 553–80. doi:10.1146/annurev-clinpsy-032813-153705. PMC 4197852. PMID 24313567.

^ a b c d e f g h i "Depakote- divalproex sodium tablet, delayed release". Archived from the original on 5 March 2016. Retrieved 10 November 2015.

^ Činčárová L, Zdráhal Z, Fajkus J (2013). "New perspectives of valproic acid in clinical practice". Expert Opin Investig Drugs. 22 (12): 1535–1547. doi:10.1517/13543784.2013.853037. PMID 24160174. S2CID 11855893.

^ a b c d e f g h i j k l m n o "Valpro sodium valproate" (PDF). TGA eBusiness Services. Alphapharm Pty Limited. 16 December 2013. Retrieved 14 February 2014.

^ "Depakote 250mg Tablets - Summary of Product Characteristics". electronic Medicines Compendium. Sanofi. 28 November 2013. Archived from the original on 1 February 2014. Retrieved 18 January 2014.

^ Neurology Department, Federal University of Santa Maria, RS, Brazil; Rissardo, Jamir Pitton; Fornari Caprara, Ana Letícia; Neurology Department, Federal University of Santa Maria, RS, Brazil; Freitas Silveira, Juliana Oliveira; Neurology Department, Federal University of Santa Maria, RS, Brazil (30 September 2019). "Valproic acid-associated pancytopenia: A dose-dependent adverse effect" (PDF). Romanian Journal of Neurology. 18 (3): 150–153. doi:10.37897/RJN.2019.3.9. S2CID 219250201.{{cite journal}}:  CS1 maint: multiple names: authors list (link)

^ Wu S, Legido A, De Luca F (2004). "Effects of valproic acid on longitudinal bone growth". J Child Neurol. 19 (1): 26–30. doi:10.1177/088307380401900105011. PMID 15032379. S2CID 19827846.

^ Robinson PB, Harvey W, Belal MS (1988). "Inhibition of cartilage growth by the anticonvulsant drugs diphenylhydantoin and sodium valproate". Br J Exp Pathol. 69 (1): 17–22. PMC 2013195. PMID 3126792.

^ Guo CY, Ronen GM, Atkinson SA (2002). "Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy". Epilepsia. 42 (9): 1141–7. doi:10.1046/j.1528-1157.2001.416800.x. PMID 11580761. S2CID 25499280.

^ Guo CY, Ronen GM, Atkinson SA (2002). "Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy". Epilepsia. 42 (9): 1141–7. doi:10.1046/j.1528-1157.2001.416800.x. PMID 11580761. S2CID 25499280.

^ "Could Depakote cause Mydriasis". eHealthMe.com. 18 November 2014. Archived from the original on 5 December 2014. Retrieved 24 April 2015.

^ Bilo, Leonilda; Meo, Roberta (October 2008). "Polycystic ovary syndrome in women using valproate: a review". Gynecological Endocrinology. 24 (10): 562–70. doi:10.1080/09513590802288259. PMID 19012099. S2CID 36426338.

^ Chukwu, J; Delanty, N; Webb, D; Cavalleri, GL (January 2014). "Weight change, genetics and antiepileptic drugs". Expert Review of Clinical Pharmacology. 7 (1): 43–51. doi:10.1586/17512433.2014.857599. PMID 24308788. S2CID 33444886.

^ New evidence in France of harm from epilepsy drug valproate Archived 21 April 2017 at the Wayback Machine BBC, 2017

^ Koch S, Göpfert-Geyer I, Jäger-Roman E,  et al. (February 1983). "[Anti-epileptic agents during pregnancy. A prospective study on the course of pregnancy, malformations and child development]". Dtsch. Med. Wochenschr. (in German). 108 (7): 250–7. doi:10.1055/s-2008-1069536. PMID 6402356.

^ Moore SJ, Turnpenny P, Quinn A,  et al. (July 2000). "A clinical study of 57 children with fetal anticonvulsant syndromes". J. Med. Genet. 37 (7): 489–97. doi:10.1136/jmg.37.7.489. PMC 1734633. PMID 10882750.

^ Ornoy A (2009). "Valproic acid in pregnancy: how much are we endangering the embryo and fetus?". Reprod. Toxicol. 28 (1): 1–10. doi:10.1016/j.reprotox.2009.02.014. PMID 19490988.

^ Kulkarni ML, Zaheeruddin M, Shenoy N, Vani HN (2006). "Fetal valproate syndrome". Indian J Pediatr. 73 (10): 937–939. doi:10.1007/bf02859291. PMID 17090909. S2CID 38371596.

^ Adab N, Kini U, Vinten J,  et al. (November 2004). "The longer term outcome of children born to mothers with epilepsy". J. Neurol. Neurosurg. Psychiatry. 75 (11): 1575–83. doi:10.1136/jnnp.2003.029132. PMC 1738809. PMID 15491979. This argues that the fetal valproate syndrome constitutes a real clinical entity that includes developmental delay and cognitive impairments, but that some children might exhibit some developmental delay without marked dysmorphism.

^ Umur AS, Selcuki M, Bursali A, Umur N, Kara B, Vatansever HS, Duransoy YK (2012). "Simultaneous folate intake may prevent adverse effect of valproic acid on neurulating nervous system". Childs Nerv Syst. 28 (5): 729–737. doi:10.1007/s00381-011-1673-9. PMID 22246336. S2CID 20344828.

^ Cassels, Caroline (8 December 2006). "NEAD: In Utero Exposure To Valproate Linked to Poor Cognitive Outcomes in Kids". Medscape. Archived from the original on 31 July 2011. Retrieved 23 May 2007.

^ Meador KJ, Baker GA, Finnell RH, Kalayjian LA, Liporace JD, Loring DW, Mawer G, Pennell PB, Smith JC, Wolff MC (2006). "In utero antiepileptic drug exposure: fetal death and malformations". Neurology. 67 (3): 407–412. doi:10.1212/01.wnl.0000227919.81208.b2. PMC 1986655. PMID 16894099.

^ Christensen J, Grønborg TK, Sørensen MJ, Schendel D, Parner ET, Pedersen LH, Vestergaard M (2013). "Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism". JAMA. 309 (16): 1696–1703. doi:10.1001/jama.2013.2270. PMC 4511955. PMID 23613074.

^ Rasalam AD, Hailey H, Williams JH,  et al. (August 2005). "Characteristics of fetal anticonvulsant syndrome associated autistic disorder". Dev Med Child Neurol. 47 (8): 551–5. doi:10.1017/S0012162205001076. PMID 16108456.

^ Autism Society of America: About Autism Archived 10 January 2011 at the Wayback Machine

^ I.Q. Harmed by Epilepsy Drug in Utero Archived 29 December 2015 at the Wayback Machine By RONI CARYN RABIN, New York Times, 15 April 2009

^ Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW (2009). "Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs". N. Engl. J. Med. 360 (16): 1597–1605. doi:10.1056/NEJMoa0803531. PMC 2737185. PMID 19369666.

^ Valproate Products: Drug Safety Communication - Risk of Impaired Cognitive Development in Children Exposed In Utero (During Pregnancy) Archived 2 September 2011 at the Wayback Machine. FDA. June 2011

^ Luat, AF (20 September 2007). "Paroxysmal tonic upgaze of childhood with co-existent absence epilepsy". Epileptic Disorders. 9 (3): 332–6. doi:10.1684/epd.2007.0119 (inactive 31 October 2021). PMID 17884759.{{cite journal}}:  CS1 maint: DOI inactive as of October 2021 (link)

^ Ouvrier, RA (July 1988). "Benign paroxysmal tonic upgaze of childhood". Journal of Child Neurology. 3 (3): 177–80. doi:10.1177/088307388800300305. PMID 3209843. S2CID 38127378.

^ Valproate Not To Be Used for Migraine During Pregnancy, FDA Warns Archived 9 July 2013 at the Wayback Machine

^ "New measures to avoid valproate exposure in pregnancy endorsed". European Medicines Agency. 31 May 2018.

^ a b c d Bentley, Suzanne (11 December 2013). "Valproic Acid Level". Medscape. Archived from the original on 4 May 2015. Retrieved 5 June 2015.

^ a b c d "Free Valproic Acid Assay (Reference – 2013.03.006) Notice of Assessment" (PDF). Canadian Agency for Drugs and Technologies in Health (CADTH) with INESSS's permission. April 2014. Archived from the original (PDF) on 3 March 2016. Retrieved 5 June 2015.

^ Rissardo, Jamir Pitton; Caprara, Ana Letícia Fornari; Durante, Ícaro (2021). "Valproate-associated Movement Disorder: A Literature Review". Prague Medical Report. 122 (3): 140–180. doi:10.14712/23362936.2021.14. ISSN 1214-6994. PMID 34606429. S2CID 238356343.

^ Sztajnkrycer MD (2002). "Valproic acid toxicity: overview and management". J. Toxicol. Clin. Toxicol. 40 (6): 789–801. doi:10.1081/CLT-120014645. PMID 12475192. S2CID 23031095.

^ Patsalos PN, Berry DJ (2013). "Therapeutic drug monitoring of antiepileptic drugs by use of saliva". Ther Drug Monit. 35 (1): 4–29. doi:10.1097/FTD.0b013e31827c11e7. PMID 23288091. S2CID 15338188.

^ Thanacoody RH (2009). "Extracorporeal elimination in acute valproic acid poisoning". Clin Toxicol. 47 (7): 609–616. doi:10.1080/15563650903167772. PMID 19656009. S2CID 13592043.

^ R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 1622–1626.

^ a b Lheureux PE, Penaloza A, Zahir S, Gris M (2005). "Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?". Crit Care. 9 (5): 431–440. doi:10.1186/cc3742. PMC 1297603. PMID 16277730.

^ Mock CM, Schwetschenau KH (2012). "Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy". Am J Health Syst Pharm. 69 (1): 35–39. doi:10.2146/ajhp110049. PMID 22180549.

^ Matsuoka M, Igisu H (1993). "Comparison of the effects of L-carnitine, D-carnitine and acetyl-L-carnitine on the neurotoxicity of ammonia". Biochem. Pharmacol. 46 (1): 159–164. doi:10.1016/0006-2952(93)90360-9. PMID 8347126.

^ Herzog, Andrew; Farina, Erin (9 June 2005). "Serum Valproate Levels with Oral Contraceptive Use". Epilepsia. 46 (6): 970–971. doi:10.1111/j.1528-1167.2005.00605.x. PMID 15946343. S2CID 7696039.

^ Kay, Hee Yeon; Greene, Derek L.; Kang, Seungwoo; Kosenko, Anastasia; Hoshi, Naoto (1 October 2015). "M-current preservation contributes to anticonvulsant effects of valproic acid". The Journal of Clinical Investigation. 125 (10): 3904–3914. doi:10.1172/JCI79727. ISSN 0021-9738. PMC 4607138. PMID 26348896.

^ Chang P, Walker MC, Williams RS (2014). "Seizure-induced reduction in PIP3 levels contributes to seizure-activity and is rescued by valproic acid". Neurobiol. Dis. 62: 296–306. doi:10.1016/j.nbd.2013.10.017. PMC 3898270. PMID 24148856.

^ Kostrouchová M, Kostrouch Z, Kostrouchová M (2007). "Valproic acid, a molecular lead to multiple regulatory pathways" (PDF). Folia Biol. (Praha). 53 (2): 37–49. PMID 17448293. Archived from the original (PDF) on 21 February 2014. Retrieved 13 February 2014.

^ a b Chiu CT, Wang Z, Hunsberger JG, Chuang DM (2013). "Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder". Pharmacol. Rev. 65 (1): 105–142. doi:10.1124/pr.111.005512. PMC 3565922. PMID 23300133.

^ a b Death AK, McGrath KC, Handelsman DJ (2005). "Valproate is an anti-androgen and anti-progestin" (PDF). Steroids. 70 (14): 946–53. doi:10.1016/j.steroids.2005.07.003. hdl:10453/16875. PMID 16165177. S2CID 25958985.

^ a b Wyllie E, Cascino GD, Gidal BE, Goodkin HP (17 February 2012). Wyllie's Treatment of Epilepsy: Principles and Practice. Lippincott Williams & Wilkins. pp. 288–. ISBN 978-1-4511-5348-4. Archived from the original on 6 June 2014.

^ Uchida, Hiroshi; Maruyama, Tetsuo; Arase, Toru; Ono, Masanori; Nagashima, Takashi; Masuda, Hirotaka; Asada, Hironori; Yoshimura, Yasunori (2005). "Histone acetylation in reproductive organs: Significance of histone deacetylase inhibitors in gene transcription". Reproductive Medicine and Biology. 4 (2): 115–122. doi:10.1111/j.1447-0578.2005.00101.x. ISSN 1445-5781. PMC 5891791. PMID 29662388.

^ a b Isojärvi, Jouko I T; Taubøll, Erik; Herzog, Andrew G (2005). "Effect of Antiepileptic Drugs on Reproductive Endocrine Function in Individuals with Epilepsy". CNS Drugs. 19 (3): 207–223. doi:10.2165/00023210-200519030-00003. ISSN 1172-7047. PMID 15740176. S2CID 9893959.

^ a b c d e f Haberfeld H, ed. (2021). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Depakine chrono retard 300 mg Filmtabletten.

^ Kumar, S.; Wong, H.; Yeung, S. A.; Riggs, K. W.; Abbott, F. S.; Rurak, D. W. (2000). "Disposition of valproic acid in maternal, fetal, and newborn sheep. II: Metabolism and renal elimination". Drug Metabolism and Disposition: The Biological Fate of Chemicals. 28 (7): 857–864. PMID 10859160.

^ Schneemann; Young, Lloyd; Koda-Kimble, Mary Anne, eds. (2001). Angewandte Arzneimitteltherapie (in German). Springer. pp. 28–29. ISBN 3540413561.

^ a b Valproate FDA Professional Drug Information. Accessed 6 August 2021.

^ a b c d e f g h "Pharmacology". Valproic Acid. DrugBank. University of Alberta. 31 August 2017.

^ Burton BS (1882). "On the propyl derivatives and decomposition products of ethylacetoacetate". Am. Chem. J. 3: 385–395.

^ Meunier H, Carraz G, Neunier Y, Eymard P, Aimard M (1963). "[Pharmacodynamic properties of N-dipropylacetic acid]" [Pharmacodynamic properties of N-dipropylacetic acid]. Thérapie (in French). 18: 435–438. PMID 13935231.

^ Perucca E (2002). "Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience". CNS Drugs. 16 (10): 695–714. doi:10.2165/00023210-200216100-00004. PMID 12269862. S2CID 803106.

^ Henry TR (2003). "The history of valproate in clinical neuroscience". Psychopharmacol Bull. 37 Suppl 2: 5–16. PMID 14624229.

^ Joint Formulary Committee (2013). British National Formulary (BNF) (65 ed.). London, UK: Pharmaceutical Press. ISBN 978-0-85711-084-8.

^ Rimmer EM, Richens A (May–June 1985). "An update on sodium valproate". Pharmacotherapy. 5 (3): 171–84. doi:10.1002/j.1875-9114.1985.tb03413.x. PMID 3927267. S2CID 7700266.

^ Glauser, Tracy A; Cnaan, Avital; Shinnar, Shlomo; Hirtz, Deborah G; Dlugos, Dennis; Masur, David; Clark, Peggy O; Capparelli, Edmund V; Adamson, Peter C (2010). "Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy". New England Journal of Medicine. 362 (9): 790–9. doi:10.1056/NEJMoa0902014. PMC 2924476. PMID 20200383.

^ Jiang, Mei (6 April 2015). "Co-Administration of Valproic Acid and Lamotrigine in the Treatment of Refractory Epilepsy (P1.238)". Neurology. 84 (14 Supplement): P1.238 – via www.neurology.org.

^ Berendsen, S.; Kroonen, J.; Seute, T.; Snijders, T.; Broekman, M. L. D.; Spliet, W. G. M.; Willems, M.; Artesi, M.; Bours, V.; Robe, P. A. (1 September 2014). "O9.06 * Prognostic Relevance and Oncogenic Correlates of Epilepsy in Glioblastoma Patients". Neuro-Oncology. 16 (suppl_2): ii21. doi:10.1093/neuonc/nou174.77. PMC 4185847.

^ Vasudev K, Mead A, Macritchie K, Young AH (2012). "Valproate in acute mania: is our practice evidence based?". International Journal of Health Care Quality Assurance. 25 (1): 41–52. doi:10.1108/09526861211192395. PMID 22455007.

^ Bond DJ, Lam RW, Yatham LN (2010). "Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis". J Affect Disord. 124 (3): 228–334. doi:10.1016/j.jad.2009.11.008. PMID 20044142.

^ Haddad PM, Das A, Ashfaq M, Wieck A (2009). "A review of valproate in psychiatric practice". Expert Opin Drug Metab Toxicol. 5 (5): 539–51. doi:10.1517/17425250902911455. PMID 19409030. S2CID 74028228.

^ Frazee LA, Foraker KC (2008). "Use of intravenous valproic acid for acute migraine". Ann Pharmacother. 42 (3): 403–7. doi:10.1345/aph.1K531. PMID 18303140. S2CID 207263036.

^ Wang, Yijun; Xia, Jun; Helfer, Bartosz; Li, Chunbo; Leucht, Stefan (2016). "Valproate for schizophrenia". The Cochrane Database of Systematic Reviews. 2016 (11): CD004028. doi:10.1002/14651858.CD004028.pub4. ISSN 1469-493X. PMC 6734130. PMID 27884042.

^ a b Baillon, Sarah F.; Narayana, Usha; Luxenberg, Jay S.; Clifton, Andrew V. (5 October 2018). "Valproate preparations for agitation in dementia". The Cochrane Database of Systematic Reviews. 2018 (10): CD003945. doi:10.1002/14651858.CD003945.pub4. ISSN 1469-493X. PMC 6516950. PMID 30293233.

^ Gill D, Derry S, Wiffen PJ, Moore RA (2011). "Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults". Cochrane Database Syst Rev (10): CD009183. doi:10.1002/14651858.CD009183.pub2. PMC 6540387. PMID 21975791.

^ Aliyev ZN, Aliyev NA (July–August 2008). "Valproate treatment of acute alcohol hallucinosis: a double-blind, placebo-controlled study". Alcohol Alcohol. 43 (4): 456–459. doi:10.1093/alcalc/agn043. PMID 18495806.

^ Jacobson PL, Messenheimer JA, Farmer TW (1981). "Treatment of intractable hiccups with valproic acid". Neurology. 31 (11): 1458–60. doi:10.1212/WNL.31.11.1458. PMID 6796902. S2CID 1578958.

^ Sotaniemi K (1982). "Valproic acid in the treatment of nonepileptic myoclonus". Arch. Neurol. 39 (7): 448–9. doi:10.1001/archneur.1982.00510190066025. PMID 6808975.

^ Wheeler SD (July–August 1998). "Significance of migrainous features in cluster headache: divalproex responsiveness". Headache. 38 (7): 547–51. doi:10.1046/j.1526-4610.1998.3807547.x. PMID 15613172. S2CID 27948702.

^ Siemes H, Spohr HL, Michael T, Nau H (September–October 1988). "Therapy of infantile spasms with valproate: results of a prospective study". Epilepsia. 29 (5): 553–60. doi:10.1111/j.1528-1157.1988.tb03760.x. PMID 2842127. S2CID 23789333.

^ Smith SM (2005). "Valproic acid and HIV-1 latency: beyond the sound bite" (PDF). Retrovirology. 2 (1): 56. doi:10.1186/1742-4690-2-56. PMC 1242254. PMID 16168066. Archived from the original (PDF) on 24 September 2015. Retrieved 13 February 2014.

^ Routy JP, Tremblay CL, Angel JB, Trottier B, Rouleau D, Baril JG, Harris M, Trottier S, Singer J, Chomont N, Sékaly RP, Boulassel MR (2012). "Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study". HIV Med. 13 (5): 291–6. doi:10.1111/j.1468-1293.2011.00975.x. PMID 22276680. S2CID 27571864.

^ Archin NM, Cheema M, Parker D, Wiegand A, Bosch RJ, Coffin JM, Eron J, Cohen M, Margolis DM (2010). "Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection". PLOS ONE. 5 (2): e9390. Bibcode:2010PLoSO...5.9390A. doi:10.1371/journal.pone.0009390. PMC 2826423. PMID 20186346.

^ a b Hardy JR, Rees EA, Gwilliam B, Ling J, Broadley K, A'Hern R (2001). "A phase II study to establish the efficacy and toxicity of sodium valproate in patients with cancer-related neuropathic pain" (PDF). J Pain Symptom Manage. 21 (3): 204–9. doi:10.1016/S0885-3924(00)00266-9. PMID 11239739.[permanent dead link]

^ Candelaria M, Herrera A, Labardini J, González-Fierro A, Trejo-Becerril C, Taja-Chayeb L, Pérez-Cárdenas E, de la Cruz-Hernández E, Arias-Bofill D, Vidal S, Cervera E, Dueñas-Gonzalez A (2011). "Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial". Ann. Hematol. 90 (4): 379–387. doi:10.1007/s00277-010-1090-2. PMID 20922525. S2CID 13437134.

^ Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K, Romanski A, Kramer OH, Kampfmann M, Hoelzer D, Neubauer A, Ruthardt M, Ottmann OG (2005). "Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia". Cancer. 104 (12): 2717–2725. doi:10.1002/cncr.21589. PMID 16294345. S2CID 1802132.

^ Kuendgen A, Schmid M, Schlenk R, Knipp S, Hildebrandt B, Steidl C, Germing U, Haas R, Dohner H, Gattermann N (2006). "The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia". Cancer. 106 (1): 112–119. doi:10.1002/cncr.21552. PMID 16323176. S2CID 43747497.

^ Fredly H, Gjertsen BT, Bruserud O (2013). "Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents" (PDF). Clin Epigenetics. 5 (1): 12. doi:10.1186/1868-7083-5-12. PMC 3733883. PMID 23898968. Archived from the original (PDF) on 21 February 2014. Retrieved 13 February 2014.

^ Coronel J, Cetina L, Pacheco I, Trejo-Becerril C, González-Fierro A, de la Cruz-Hernandez E, Perez-Cardenas E, Taja-Chayeb L, Arias-Bofill D, Candelaria M, Vidal S, Dueñas-González A (2011). "A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results". Med. Oncol. 28 Suppl 1: S540–6. doi:10.1007/s12032-010-9700-3. PMID 20931299. S2CID 207372333.

^ Rocca A, Minucci S, Tosti G, Croci D, Contegno F, Ballarini M, Nolè F, Munzone E, Salmaggi A, Goldhirsch A, Pelicci PG, Testori A (2009). "A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma". Br. J. Cancer. 100 (1): 28–36. doi:10.1038/sj.bjc.6604817. PMC 2634690. PMID 19127265.

^ Munster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B, Daud A, Neuger A, Minton S, Sullivan D (2009). "Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC" (PDF). Clin. Cancer Res. 15 (7): 2488–96. doi:10.1158/1078-0432.CCR-08-1930. PMID 19318486. S2CID 3230087.

^ Hicks CW, Pandya MM, Itin I, Fernandez HH (2011). "Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's disease". Parkinsonism Relat. Disord. 17 (5): 379–81. doi:10.1016/j.parkreldis.2011.03.003. PMID 21459656.

^ Sriram A, Ward HE, Hassan A, Iyer S, Foote KD, Rodriguez RL, McFarland NR, Okun MS (2013). "Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease". J. Neurol. 260 (2): 521–7. doi:10.1007/s00415-012-6669-1. PMID 23007193. S2CID 21544457.

^ Aizenman, N. C. (7 May 2012). "Abbott Laboratories to pay $1.6 billion over illegal marketing of Depakote". Washington Post. Retrieved 27 June 2018.

^ Schmidt, Michael; Thomas, Katie (8 May 2012). "Abbott settles marketing lawsuit". New York Times. Retrieved 27 June 2018.

^ Gervain J, Vines BW, Chen LM, Seo RJ, Hensch TK, Werker JF, Young AH (2013). "Valproate reopens critical-period learning of absolute pitch". Frontiers in Systems Neuroscience. 7: 102. doi:10.3389/fnsys.2013.00102. PMC 3848041. PMID 24348349.

^ Thomson, Helen. "Learning drugs reawaken grown-up brain's inner child". New Scientist. New Scientist Ltd. Retrieved 8 May 2021.

^ David Taylor; Carol Paton; Shitij Kapur (2009). The Maudsley Prescribing Guidelines, Tenth Edition (10, revised ed.). CRC Press. p. 124. ISBN 9780203092835.

^ "Depakene- valproic acid capsule, liquid filled". DailyMed. 19 September 2019. Retrieved 14 April 2020.

^ a b c d "Australian product information epilim (sodium valproate) crushable tablets, enteric-coated tablets, syrup, liquid" (PDF). TGA eBS. 15 April 2020. Retrieved 15 April 2020.

^ "Sodium valproate -- Pharmaceutical Schedule". Pharmaceutical Management Agency. Archived from the original on 4 March 2016. Retrieved 22 June 2014.

^ "South African Electronic Package Inserts: Convulex". Archived from the original on 12 August 2010. Retrieved 2 January 2006.


External links[edit]
"Valproic acid". Drug Information Portal. U.S. National Library of Medicine.
"Valproate sodium". Drug Information Portal. U.S. National Library of Medicine.
"Divalproex sodium". Drug Information Portal. U.S. National Library of Medicine.
.mw-parser-output .navbox{box-sizing:border-box;border:1px solid #a2a9b1;width:100%;clear:both;font-size:88%;text-align:center;padding:1px;margin:1em auto 0}.mw-parser-output .navbox .navbox{margin-top:0}.mw-parser-output .navbox+.navbox,.mw-parser-output .navbox+.navbox-styles+.navbox{margin-top:-1px}.mw-parser-output .navbox-inner,.mw-parser-output .navbox-subgroup{width:100%}.mw-parser-output .navbox-group,.mw-parser-output .navbox-title,.mw-parser-output .navbox-abovebelow{padding:0.25em 1em;line-height:1.5em;text-align:center}.mw-parser-output .navbox-group{white-space:nowrap;text-align:right}.mw-parser-output .navbox,.mw-parser-output .navbox-subgroup{background-color:#fdfdfd}.mw-parser-output .navbox-list{line-height:1.5em;border-color:#fdfdfd}.mw-parser-output .navbox-list-with-group{text-align:left;border-left-width:2px;border-left-style:solid}.mw-parser-output tr+tr>.navbox-abovebelow,.mw-parser-output tr+tr>.navbox-group,.mw-parser-output tr+tr>.navbox-image,.mw-parser-output tr+tr>.navbox-list{border-top:2px solid #fdfdfd}.mw-parser-output .navbox-title{background-color:#ccf}.mw-parser-output .navbox-abovebelow,.mw-parser-output .navbox-group,.mw-parser-output .navbox-subgroup .navbox-title{background-color:#ddf}.mw-parser-output .navbox-subgroup .navbox-group,.mw-parser-output .navbox-subgroup .navbox-abovebelow{background-color:#e6e6ff}.mw-parser-output .navbox-even{background-color:#f7f7f7}.mw-parser-output .navbox-odd{background-color:transparent}.mw-parser-output .navbox .hlist td dl,.mw-parser-output .navbox .hlist td ol,.mw-parser-output .navbox .hlist td ul,.mw-parser-output .navbox td.hlist dl,.mw-parser-output .navbox td.hlist ol,.mw-parser-output .navbox td.hlist ul{padding:0.125em 0}.mw-parser-output .navbox .navbar{display:block;font-size:100%}.mw-parser-output .navbox-title .navbar{float:left;text-align:left;margin-right:0.5em}.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:"[ "}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:" ]"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar a>span,.mw-parser-output .navbar a>abbr{text-decoration:inherit}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}vteAnticonvulsants (N03)GABAergicsGABAAR PAMs
Barbiturates: Barbexaclone
Metharbital
Methylphenobarbital
Pentobarbital
Phenobarbital#
Primidone; Carbamates: Cenobamate
Felbamate; Benzodiazepines: Clobazam
Clonazepam
Clorazepate
Diazepam#
Lorazepam#
Midazolam
Nimetazepam
Nitrazepam
Temazepam; Others: Bromide (potassium bromide, sodium bromide)
Imepitoin
Paraldehyde
Stiripentol
GABA-T inhibitors
Fatty acids (and related): Valproate
Valpromide
Valproate pivoxil
Vigabatrin
Others
GABAR agonists: Progabide; GAT-1 inhibitors: Tiagabine
ChannelmodulatorsSodium blockers
Hydantoins: Ethotoin
Fosphenytoin
Mephenytoin
Phenytoin#; Ureides: Acetylpheneturide
Chlorphenacemide
Phenacemide‡
Pheneturide; Fatty acids: Valproate
Valpromide
Valproate pivoxil; Carboxamides: Brivaracetam
Carbamazepine#
Eslicarbazepine acetate
Oxcarbazepine; Others: Lacosamide
Lamotrigine#
Rufinamide
Topiramate
Zonisamide
Calcium blockers
Oxazolidinediones: Ethadione
Paramethadione
Trimethadione; Succinimides: Ethosuximide#
Mesuximide
Phensuximide; Gabapentinoids: Gabapentin
Pregabalin; Others: Imepitoin
Lamotrigine#
Topiramate
Zonisamide
Potassium openers
Retigabine
OthersCA inhibitors
Sulfonamides: Acetazolamide
Ethoxzolamide
Sultiame
Topiramate
Zonisamide
Others
Albutoin
Beclamide
Cannabidiol
Etiracetam
Levetiracetam
Perampanel

#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III

vteMood stabilizersAnticonvulsants
Carbamazepine
Lamotrigine
Oxcarbazepine
Valproate
Valnoctamide
Valproate pivoxil
Valpromide
Atypical antipsychotics
Aripiprazole
Asenapine
Cariprazine
Clozapine
Lurasidone
Olanzapine (+fluoxetine)
Paliperidone
Quetiapine
Risperidone
Ziprasidone
Others
Ketamine
Lithium (lithium acetate, lithium carbonate, lithium chloride, lithium citrate, lithium hydroxide, lithium orotate)
Omega-3 fatty acids (docosahexaenoic acid, eicosapentaenoic acid)

Pharmacodynamics
vteAndrogen receptor modulatorsARAgonists
Testosterone derivatives: 4-Androstenediol
4-Dehydroepiandrosterone (4-DHEA)
4-Hydroxytestosterone
4,17α-Dimethyltestosterone
5-Androstenedione
11-Ketotestosterone
11β-Hydroxyandrostenedione
Adrenosterone (11-ketoandrostenedione, 11-oxoandrostenedione)
Androstenediol (5-androstenediol)
Androstenediol 3β-acetate
Androstenediol 17β-acetate
Androstenediol diacetate
Androstenediol dipropionate
Androstenedione (4-androstenedione)
Atamestane
Boldenone
Boldenone undecylenate
Boldione (1,4-androstadienedione)
Clostebol
Clostebol acetate
Clostebol caproate
Clostebol propionate
Cloxotestosterone
Cloxotestosterone acetate
Dehydroandrosterone
DHEA (androstenolone, prasterone; 5-DHEA)
DHEA enanthate (prasterone enanthate)
DHEA sulfate
Exemestane
Formestane
Plomestane
Quinbolone
Silandrone
Testosterone# (+dutasteride)
Testosterone esters
Polytestosterone phloretin phosphate
5α-Dihydrotestosterone derivatives: 1-Androstenediol
1-Androstenedione
1-Androsterone (1-andro, 1-DHEA)
1-Testosterone
3α-Androstanediol
5α-Androst-2-en-17-one
7β-Hydroxyepiandrosterone
11-Ketodihydrotestosterone
Androsterone
Bolazine
Bolazine capronate
Dihydroethyltestosterone
Dihydrofluoxymesterone
Dihydromethylandrostenediol
Dihydrotestosterone (DHT) (androstanolone, stanolone)
Dihydrotestosterone esters
Drostanolone
Drostanolone propionate
Epiandrosterone
Epitiostanol
Mepitiostane
Mesabolone
Mesterolone
Mesterolone cipionate
Methyldiazinol
Nisterime
Nisterime acetate
Prostanozol
Stenbolone
Stenbolone acetate
Testifenon (testiphenon, testiphenone)
19-Nortestosterone derivatives: 7α-Methyl-19-norandrostenedione (MENT dione, trestione)
11β-Methyl-19-nortestosterone
11β-Methyl-19-nortestosterone dodecylcarbonate
19-Nor-5-androstenediol
19-Nor-5-androstenedione
19-Nordehydroepiandrosterone
Bolandiol
Bolandiol dipropionate
Bolandione (19-nor-4-androstenedione)
Bolmantalate (nandrolone adamantoate)
Dienedione
Dienolone
Dimethandrolone
Dimethandrolone buciclate
Dimethandrolone dodecylcarbonate
Dimethandrolone undecanoate
LS-1727 (nandrolone 17β-N-(2-chloroethyl)-N-nitrosocarbamate)
Methoxydienone (methoxygonadiene)
Nandrolone
Nandrolone esters
Norclostebol
Norclostebol acetate
Normethandrone (methylestrenolone, normethisterone)
Oxabolone
Oxabolone cipionate (oxabolone cypionate)
Trenbolone
Trenbolone acetate
Trenbolone enanthate
Trenbolone hexahydrobenzylcarbonate
Trenbolone undecanoate
Trendione
Trestolone (MENT)
Trestolone acetate
Trestolone enanthate
5α-Dihydro-19-nortestosterone derivatives: 5α-Dihydronandrolone
5α-Dihydrotrestolone
19-Norandrosterone
17α-Alkylated testosterone derivatives: Bolasterone
Calusterone
Chlorodehydromethylandrostenediol (CDMA)
Chlorodehydromethyltestosterone (CDMT)
Chloromethylandrostenediol (CMA)
Enestebol
Ethyltestosterone
Fluoxymesterone
Formebolone
Hydroxystenozole
Metandienone (methandrostenolone)
Methandriol (methylandrostenediol)
Methandriol bisenanthoyl acetate
Methandriol diacetate
Methandriol dipropionate
Methandriol propionate
Methylclostebol (chloromethyltestosterone)
Methyltestosterone (+esterified estrogens)
Methyltestosterone 3-hexyl ether
Oxymesterone
Penmesterol
Tiomesterone
17α-Alkylated 5α-dihydrotestosterone derivatives: Androisoxazole
Desoxymethyltestosterone
Furazabol
Mebolazine (dimethazine)
Mestanolone
Metenolone
Metenolone acetate
Metenolone enanthate
Methasterone
Methyl-1-testosterone
Methylepitiostanol
Methylstenbolone
Oxandrolone
Oxymetholone
Stanozolol
17α-Alkylated 19-nortestosterone derivatives: Bolenol
Dimethyldienolone
Dimethyltrienolone
Ethyldienolone
Ethylestrenol
Methyldienolone
Methylhydroxynandrolone (MOHN, MHN)
Metribolone
Mibolerone
Norboletone
Norethandrolone
Propetandrol
RU-2309
Tetrahydrogestrinone
17α-Alkylated 5α-dihydro-19-nortestosterone derivatives: 5α-Dihydronorethandrolone
5α-Dihydronormethandrone
17α-Vinyltestosterone derivatives: Norvinisterone (vinylnortestosterone)
17α-Vinyl-19-nortestosterone derivatives: Vinyltestosterone
17α-Ethynyltestosterone derivatives: Danazol
Ethinylandrostenediol
Ethandrostate
Ethisterone (ethynyltestosterone)
5α-Dihydro-17α-ethynyltestosterone derivatives: 17α-Ethynyl-3α-androstanediol
17α-Ethynyl-3β-androstanediol
Dihydroethisterone
17α-Ethynyl-19-nortestosterone derivatives: Δ4-Tibolone
Desogestrel
Etonogestrel
Etynodiol
Etynodiol diacetate
Gestodene
Gestrinone
Levonorgestrel
Levonorgestrel esters (e.g., levonorgestrel butanoate)
Lynestrenol
Lynestrenol phenylpropionate
Norethisterone
Norethisterone esters (e.g., norethisterone acetate, norethisterone enanthate)
Norgestrel
Norgestrienone
Quingestanol
Quingestanol acetate
Tibolone
5α-Dihydro-17α-ethynyl-19-nortestosterone derivatives: 5α-Dihydrolevonorgestrel
5α-Dihydronorethisterone
Progesterone derivatives: 6α-Methylprogesterone
Medroxyprogesterone acetate
Megestrol acetate
Others/unsorted: 3-Keto-5α-abiraterone
5α-Androstane
Alternariol
Cl-4AS-1
Drupanol
Trilostane
ZM-182345
Mixed(SARMs)
Nonsteroidal: 198RL26
ACP-105
AC-262536
Acetothiolutamide
Acetoxolutamide
Andarine (acetamidoxolutamide, androxolutamide, GTx-007, S-4)
BMS-564929
DTIB
Enobosarm (ostarine, MK-2866, GTx-024, S-22)
FTBU-1
GLPG-0492
GSK2881078
GSK-4336A
GSK-8698
LG-121071 (LGD-121071)
LGD-2226
LGD-2941 (LGD-122941)
LGD-3303
LGD-4033
LY-2452473
JNJ-26146900
JNJ-28330835
JNJ-37654032
ORM-11984
PF-06260414
R-1
RAD140
RU-59063
S-1
S-23
S-40503
S-101479
Triclosan
Steroidal: EM-9017
MK-0773
TFM-4AS-1
YK-11
Antagonists
Steroidal: 7α-Thioprogesterone
7α-Thiospironolactone
7α-Thiomethylspironolactone
11α-Hydroxyprogesterone
15β-Hydroxycyproterone acetate
Abiraterone
Abiraterone acetate
Allyltestosterone
Benorterone
BOMT
Canrenoic acid
Canrenone
Chlormadinone acetate
Clascoterone
Clometerone
Cyproheptadine
Cyproterone
Cyproterone acetate
Delanterone
Delmadinone acetate
Dicirenone
Dienogest
Drospirenone
DU-41165
Edogestrone
EM-4350
EM-5854
EM-5855
EM-6537
Epitestosterone
Galeterone
Guggulsterone
Ludaterone
Medrogestone
Megestrol acetate
Mespirenone
Metogest
Mexrenone
Mifepristone
Nomegestrol acetate
Nordinone
Osaterone
Osaterone acetate
Oxendolone
Potassium canrenoate
Promegestone
Prorenone
Rosterolone
RU-15328
SC-5233 (spirolactone)
Spironolactone
Spirorenone
Spiroxasone
Topterone
Trimegestone
Trimethyltrienolone (R-2956)
Zanoterone
Nonsteroidal: 5N-Bicalutamide
AA560
Antarlides
Arabilin
Apalutamide
Atraric acid
AZD-3514
Bakuchiol
Bavdegalutamide
BAY-1024767
Bicalutamide
Bisphenols (e.g., BADGE, BFDGE, bisphenol A, bisphenol F, bisphenol S)
BMS-501949
BMS-570511
BMS-641988
CH5137291
Cimetidine
Cioteronel
Cyanonilutamide
Darolutamide
DDT (via metabolite p,p’-DDE)
Dieldrin
DIMP
Endosulfan
Enzalutamide
EPI-001
EPI-7386
Fenarimol
Flutamide
Hydroxyflutamide
Inocoterone
Inocoterone acetate
Ketoconazole
Ketodarolutamide
Lavender oil
LG-105
LG-120907
LGD-1331
Linuron
Methiocarb
N-Butylbenzenesulfonamide
N-Desmethylapalutamide
N-Desmethylenzalutamide
Nilutamide
ONC1-13B
Pentomone
PF-998425
Phenothrin
Prochloraz
Procymidone
Proxalutamide
Ralaniten (EPI-002)
Ralaniten acetate (EPI-506)
RD-162
Rezvilutamide
Ro 2-7239
Ro 5-2537
RU-22930
RU-56187
RU-57073
RU-58642
RU-58841
Seviteronel
Thalidomide
Topilutamide (fluridil)
Valproic acid
Vinclozolin
YM-580
YM-92088
YM-175735
GPRC6AAgonists
Cations (incl. aluminum, calcium, gadolinium, magnesium, strontium, zinc)
Dehydroandrosterone
Dihydrotestosterone
Estradiol
L-α-Amino acids (incl. L-arginine, L-lysine, L-ornithine)
Osteocalcin
SHBG
Testosterone

See also
Receptor/signaling modulators
Androgens and antiandrogens
Estrogen receptor modulators
Progesterone receptor modulators
List of androgens/anabolic steroids

vteGABA metabolism and transport modulatorsTransporterGAT
Inhibitors: 4-Aminovaleric acid
β-Alanine
Arecaidine
CI-966
DABA
Deramciclane (EGIS-3886, EGYT-3886)
EF-1502
Gabaculine
Guvacine
Ibotenic acid
Muscimol
Nipecotic acid
NNC 05-2090
NO-711
Riluzole
SKF-89976A
SNAP-5114
TACA
Tiagabine
VIAAT
Inhibitors: β-Alanine
Bafilomycin A1
Chicago sky blue 6B
Evans blue
GABA
Glycine
N-Butyric acid
Nigericin
Nipecotic acid
Valinomycin
Vigabatrin
EnzymeGAD
Inhibitors: 3-Mercaptopropionic acid
AAOA
L-Allylglycine
Semicarbazide
GABA-T
Inhibitors: 3-Hydrazinopropionic acid
γ-Acetylenic-GABA
AOAA
EOS
Gabaculine
Isoniazid
L-Cycloserine
Phenelzine
PEH
Rosmarinic acid (lemon balm)
Sodium valproate
Valnoctamide
Valproate pivoxil
Valproate semisodium (divalproex sodium)
Valproic acid
Valpromide
Vigabatrin
Activators: 3-Methyl-GABA

See also
Receptor/signaling modulators 
GABA receptor modulators 
GABAA receptor positive modulators 
Glutamate metabolism/transport modulators 

vteHistone deacetylase inhibitors
3,3'-Diindolylmethane
β-Hydroxybutyric acid (β-hydroxybutyrate)
Abexinostat
Acetoacetic acid (acetoacetate)
Allyl mercaptan
Apicidin
Belinostat
Butyric acid (butyrate)
Capsaicin
Citarinostat
Curcumin
Diallyl disulfide
Entinostat
Fimepinostat
Givinostat
Indole-3-carbinol
Kevetrin
Martinostat
Mocetinostat
Niacinamide
Panobinostat
Parthenolide
Phenylbutyrate
Pracinostat
Quisinostat
Resminostat
Romidepsin
Scriptaid
Sodium butyrate
Sodium oxybate (GHB sodium)
Sodium phenylbutyrate
Sodium valproate
Sulforaphane
Trapoxin B
Trichostatin A
Tucidinostat
Valnoctamide
Valproic acid (valproate)
Valproate pivoxil
Valproate semisodium
Valpromide
Vorinostat (SAHA)
See also: Receptor/signaling modulators
vteIon channel modulatorsCalciumVDCCsBlockers
L-type-selective: Dihydropyridines: Amlodipine
Aranidipine
Azelnidipine
Barnidipine
Clevidipine
Cronidipine
Darodipine
Dexniguldipine
Elgodipine
Elnadipine
Felodipine
Flordipine
Furnidipine
Iganidipine
Isradipine
Lacidipine
Lemildipine
Lercanidipine
Levamlodipine
Levniguldipine
Manidipine
Mepirodipine
Mesudipine
Nicardipine
Nifedipine
Niguldipine
Niludipine
Nilvadipine
Nimodipine
Nisoldipine
Nitrendipine
Olradipine
Oxodipine
Palonidipine
Pranidipine
Ryodipine (riodipine)
Sagandipine
Sornidipine
Teludipine
Tiamdipine
Trombodipine
Vatanidipine; Diltiazem derivatives: Clentiazem
Diltiazem
Iprotiazem
Nictiazem
Siratiazem; Phenylalkylamines: Anipamil
Dagapamil
Devapamil
Dexverapamil
Emopamil
Etripamil
Falipamil
Gallopamil
Levemopamil
Nexopamil
Norverapamil
Ronipamil
Tiapamil
Verapamil; Others: AH-1058
Brinazarone
Budiodarone
Celivarone
Cyproheptadine
Dronedarone
Fantofarone
SR-33805
Tetrahydropalmatine
N-type-selective: ω-Conotoxins
ω-Conotoxin GVIA
Caroverine
Huwentoxin XVI
Leconotide (ω-conotoxin CVID)
PD-173212
Ralfinamide
Safinamide
Z160
Ziconotide (ω-conotoxin MVIIA)
P-type-selective: ω-Agatoxin IVA
ω-Agatoxin IVB
R-type-selective: SNX-482
T-type-selective: ABT-639
ML-218
Niflumic acid
NNC 55-0396
ProTx I
Z944
Zonisamide
Non-selective: ω-Agatoxin TK
ω-Conotoxin MVIIC
Benidipine
Bepridil
Cilnidipine
Cinnarizine
Dotarizine
Efonidipine
Flunarizine
Lamotrigine
Levetiracetam
Lomerizine
Loperamide
Mibefradil
NP078585
Ruthenium red
TROX-1
α2δ subunit-selective (gabapentinoids): 4-Methylpregabalin
Arbaclofen
Arbaclofen placarbil
Atagabalin
Baclofen
Gabapentin
Gabapentin enacarbil
Imagabalin
Mirogabalin
PD-200,347
PD-217,014
PD-299,685
Phenibut
Pregabalin
Others/unsorted: Bencyclane
Berbamine
Bevantolol
Canadine
Carboxyamidotriazole
Cycleanine
Dauricine
Dimeditiapramine
Diproteverine
Enpiperate
Eperisone
Elpetrigine
Ethadione
Ethanol (alcohol)
Ethosuximide
Fasudil
Fendiline
Fostedil
Imepitoin
JTV-519
Lidoflazine
Magnesium
Manoalide
Mesuximide
Monatepil
Naftopidil
Ochratoxin A
Osthol
Otilonium bromide
Paramethadione
Phensuximide
Pinaverium bromide
Prenylamine
Rhynchophylline
Sesamodil
Silperisone
Sipatrigine
Terodiline
Tetrandrine
Tolperisone
Trimethadione
Valperinol
Activators
L-type-selective: Bay K8644
PotassiumVGKCsBlockers
3,4-Diaminopyridine (amifampridine)
4-Aminopyridine (fampridine/dalfampridine)
Adekalant
Almokalant
Amiodarone
Azimilide
Bretylium
Bunaftine
Charybdotoxin
Clamikalant
Conotoxins
Dalazatide
Dendrotoxin
Dofetilide
Dronedarone
E-4031
Hanatoxin
HgeTx1
HsTx1
Ibutilide
Inakalant
Kaliotoxin
Linopirdine
Lolitrem B
Maurotoxin
Nifekalant
Notoxin
Paxilline
Pinokalant
Quinidine
ShK-186
Sotalol
Tedisamil
Terikalant
Tetraethylammonium
Vernakalant
hERG (KCNH2, Kv11.1)-specific: Ajmaline
Amiodarone
AmmTX3
Astemizole
Azaspiracid
AZD1305
Azimilide
Bedaquiline
BeKm-1
BmTx3
BRL-32872
Chlorpromazine
Cisapride
Clarithromycin
Darifenacin
Dextropropoxyphene
Diallyl trisulfide
Domperidone
E-4031
Ergtoxins
Erythromycin
Gigactonine
Haloperidol
Ketoconazole
Norpropoxyphene
Orphenadrine
Pimozide
PNU-282,987
Promethazine
Quinidine
Ranolazine
Roxithromycin
Sertindole
Solifenacin
Tamulotoxin
Terodiline
Terfenadine
Thioridazine
Tolterodine
Vanoxerine
Vernakalant
KCNQ (Kv7)-specific: Linopirdine
XE-991
Spooky toxin (SsTx)
Activators
KCNQ (Kv7)-specific: Flupirtine
Retigabine
IRKsBlockers
KATP-specific: Acetohexamide
Carbutamide
Chlorpropamide
Glibenclamide (glyburide)
Glibornuride
Glicaramide
Gliclazide
Glimepiride
Glipizide
Gliquidone
Glisoxepide
Glyclopyramide
Glycyclamide
Metahexamide
Mitiglinide
Nateglinide
Repaglinide
Tolazamide
Tolbutamide
GIRK-specific: Barium
Caramiphen
Cloperastine
Clozapine
Dextromethorphan
Ethosuximide
Ifenprodil
Tertiapin
Tipepidine
Activators
KATP-specific: Aprikalim
Bimakalim
Cromakalim
Diazoxide
Emakalim
Levcromakalim
Mazokalim
Minoxidil
Naminidil
Nicorandil
Pinacidil
Rilmakalim
Sarakalim
GIRK-specific: ML-297 (VU0456810)
KCaBlockers
BKCa-specific: Ethanol (alcohol)
GAL-021
Activators
BKCa-specific: Flufenamic acid
Meclofenamic acid
Niflumic acid
Nimesulide
Rottlerin (mallotoxin)
Tolfenamic acid
K2PsBlockers
12-O-Tetradecanoylphorbol-13-acetate
Arachidonic acid
Fluoxetine
Norfluoxetine
Activators
Riluzole
SodiumVGSCsBlockers
Antianginals: Ranolazine
Antiarrhythmics (class I): Ajmaline
Aprindine
Disopyramide
Dronedarone
Encainide
Flecainide
Lidocaine
Lorajmine
Lorcainide
Mexiletine
Moricizine
Pilsicainide
Prajmaline
Procainamide
Propafenone
Quinidine
Sparteine
Tocainide
Anticonvulsants: Acetylpheneturide
Carbamazepine
Cenobamate
Chlorphenacemide
Elpetrigine
Eslicarbazepine acetate
Ethotoin
Fosphenytoin
Lacosamide
Licarbazepine
Mephenytoin
Oxcarbazepine
Oxitriptyline
Phenacemide
Pheneturide
Phenytoin
Rufinamide
Sipatrigine
Topiramate
Sodium valproate
Valnoctamide
Valproate pivoxil
Valproate semisodium
Valproic acid
Valpromide
Zonisamide
Local anesthetics: pFBT
Amylocaine
Articaine
Benzocaine
Bupivacaine (Levobupivacaine, Ropivacaine)
Butacaine
Butamben
Chloroprocaine
Cinchocaine
Cocaine
Cyclomethycaine
Dimethocaine
Diphenhydramine
Etidocaine
Hexylcaine
Iontocaine
Lidocaine
Mepivacaine
Meprylcaine
Metabutoxycaine
Orthocaine
Piperocaine
Prilocaine
Procaine
Propoxycaine
Proxymetacaine
Risocaine
Tetracaine
Trimecaine
Analgesics: AZD-3161
DSP-2230
Funapide
GDC-0276
NKTR-171
PF-04531083
PF-05089771
Ralfinamide
Raxatrigine
RG7893 (GDC-0287)
Toxins: Conotoxins
Neosaxitoxin
Saxitoxin
Tetrodotoxin
Zetekitoxin AB
Others: Buprenorphine
Evenamide
Menthol (mint)
Safinamide
Tricyclic antidepressants
Activators
Aconitine
Atracotoxins (ω-Atracotoxin, Robustoxin, Versutoxin)
Batrachotoxin
Ciguatoxins
Grayanotoxins
Poneratoxin
ENaCBlockers
Amiloride
Benzamil
Triamterene
Activators
Solnatide
ASICsBlockers
A-317567
Amiloride
Aspirin
Ibuprofen
PcTX1
ChlorideCaCCsBlockers
Crofelemer
DIDS
Ethacrynic acid
Flufenamic acid
Fluoxetine
Furosemide
Glibenclamide
Mefloquine
Mibefradil
Niflumic acid
Activators
Carbachol
CFTRBlockers
Glibenclamide
Lonidamine
Piretanide
Activators
1,7-Phenanthroline
1,10-Phenanthroline
4,7-Phenanthroline
7,8-Benzoquinoline
Ivacaftor
Phenanthridine
UnsortedBlockers
Bumetanide
Flufenamic acid
Meclofenamic acid
Mefenamic acid
Mepacrine
Niflumic acid
Talniflumate
Tolfenamic acid
Trifluoperazine
OthersTRPs
See here instead.
LGICs
See here instead.
See also: Receptor/signaling modulators • Transient receptor potential channel modulators
vteProgesterone receptor modulatorsPRAgonists
Progesterone derivatives: 3β-Dihydroprogesterone
5α-Dihydroprogesterone
6α-Methylprogesterone
9α-Bromo-11-ketoprogesterone
11-Dehydroprogesterone
11-Deoxycorticosterone
16α-Hydroxyprogesterone
17α-Methyl-11-deoxycorticosterone acetate
20α-Dihydroprogesterone
20β-Dihydroprogesterone
Dimepregnen
Diosgenin
P1-185
Progesterone
Progesterone 3-acetyl enol ether
Quingestrone
Retroprogesterone derivatives: 20α-Dihydrodydrogesterone
20α-Dihydrotrengestone
DU-41164
DU-41165
Dydrogesterone
Retroprogesterone
Ro 6-3129
Trengestone
17α-Substituted progesterone derivatives: 6α-Methyl-17α-bromoprogesterone
15β-Hydroxycyproterone acetate
16-Methylene-17α-hydroxyprogesterone acetate
17α-Bromoprogesterone
17α-Hydroxyprogesterone (hydroxyprogesterone)
17α-Methylprogesterone
Acetomepregenol (mepregenol diacetate)
Algestone
Algestone acetonide
Algestone acetophenide
Anagestone
Anagestone acetate
Bromethenmadinone
Bromethenmadinone acetate
Butagest (buterol)
Chlormadinone
Chlormadinone acetate
Chlormadinone caproate
Chlormethenmadinone
Chlormethenmadinone acetate
Cismadinone
Cismadinone acetate
Clogestone
Clogestone acetate
Clomegestone
Clomegestone acetate
Cymegesolate
Cyproterone acetate
Delmadinone
Delmadinone acetate
Edogestrone
Flugestone
Flugestone acetate
Fluorometholone
Fluorometholone acetate
Flumedroxone
Flumedroxone acetate
Fluoromedroxyprogesterone acetate
Gestaclone
Gestobutanoyl
Haloprogesterone
Hydromadinone
Hydromadinone acetate
Hydroxyprogesterone acetate
Hydroxyprogesterone caproate (hydroxyprogesterone hexanoate)
Hydroxyprogesterone heptanoate (hydroxyprogesterone enanthate)
Hydroxyprogesterone heptanoate benzilic acid hydrazone
Mecigestone (pentarane B)
Medrogestone
Medroxyprogesterone
Medroxyprogesterone acetate
Medroxyprogesterone caproate
Megestrol
Megestrol acetate
Megestrol caproate
Melengestrol
Melengestrol acetate
Methenmadinone
Methenmadinone acetate
Methenmadinone caproate
Mometasone
Mometasone furoate
Osaterone
Osaterone acetate
Pentagestrone
Pentagestrone acetate
Pentarane A
Proligestone
Triamcinolone acetonide
19-Norprogesterone derivatives: 17α-Methyl-19-norprogesterone
18-Methylsegesterone acetate
19-Norprogesterone
Amadinone
Amadinone acetate
Demegestone
Fluoro ethyl norprogesterone
Fluoro furanyl norprogesterone
Gestadienol
Gestadienol acetate
Gestonorone acetate (gestronol acetate)
Gestonorone caproate (gestronol hexanoate)
Gestronol (gestonorone)
Nomegestrol
Nomegestrol acetate
Norgestomet
ORG-2058
Oxogestone
Oxogestone phenpropionate (xinogestone)
Promegestone
Segesterone
Segesterone acetate (nestorone)
Trimegestone
Testosterone derivatives: Progestins: 6,6-Difluoronorethisterone
6,6-Difluoronorethisterone acetate
17α-Allyl-19-nortestosterone
Allylestrenol
Altrenogest
Chloroethynylnorgestrel
Cingestol
Danazol
Desogestrel
Dienogest
Ethinylandrostenediol
Ethandrostate
Ethisterone
Ethynerone
Etonogestrel
Etynodiol
Etynodiol diacetate
Gestodene
Gestrinone
Levonorgestrel
Levonorgestrel esters (e.g., levonorgestrel butanoate)
Lynestrenol
Lynestrenol phenylpropionate
Metynodiol
Metynodiol diacetate
Norelgestromin
Norethisterone (norethindrone)
Norethisterone esters (e.g., norethisterone acetate, norethisterone enanthate)
Noretynodrel
Norgesterone
Norgestimate
Norgestrel
Norgestrienone
Norvinisterone
Oxendolone
Quingestanol
Quingestanol acetate
Tibolone
Tigestol
Tosagestin; Anabolic–androgenic steroids: 11β-Methyl-19-nortestosterone
11β-Methyl-19-nortestosterone dodecylcarbonate
19-Nor-5-androstenediol
19-Nor-5-androstenedione
19-Nordehydroepiandrosterone
Bolandiol
Bolandiol dipropionate
Bolandione
Dimethisterone
Dienedione
Dienolone
Dimethandrolone
Dimethandrolone buciclate
Dimethandrolone dodecylcarbonate
Dimethandrolone undecanoate
Dimethyldienolone
Dimethyltrienolone
Ethyldienolone
Ethylestrenol (ethylnandrol)
Methyldienolone
Metribolone (R-1881)
Methoxydienone (methoxygonadiene)
Mibolerone
Nandrolone
Nandrolone esters (e.g., nandrolone decanoate, nandrolone phenylpropionate)
Norethandrolone
Normethandrone (methylestrenolone, normethandrolone, normethisterone)
RU-2309
Tetrahydrogestrinone
Trenbolone (trienolone)
Trenbolone esters (e.g., trenbolone acetate, trenbolone enanthate)
Trendione
Trestolone
Trestolone acetate
Spirolactone derivatives: Canrenoic acid
Canrenone
Drospirenone
Mespirenone
Potassium canrenoate
Prorenone
SC-5233 (spirolactone)
SC-8109
Spironolactone
Spirorenone
Nonsteroidal: 3,8-Dihydrodiligustilide
LG-2527
LG-100128
Riligustilide
RWJ-26819
RWJ-49853
RWJ-60130
Tanaproget
ZM-182345
Unknown: ORG-47241
ORG-201745
Mixed(SPRMs)
Steroidal: Dihydroethisterone
5α-Dihydrolevonorgestrel
5α-Dihydronorethisterone
Asoprisnil
Asoprisnil ecamate
Guggulsterone
J1042
LG-120838
Metapristone (RU-42633)
Mifepristone (RU-486)
ORF-9371
ORF-9326
ORG-31710
ORG-33628
RMI-12936
Telapristone
Ulipristal acetate
Vilaprisan
ZK-137316
Nonsteroidal: Apigenin
Kaempferol
LG-120920
Naringenin
PRA-910
Syringic acid
Antagonists
Steroidal: Aglepristone
Lilopristone
Lonaprisan
Onapristone
ORG-31710
ORG-31806
ORG-33628
RTI 3021–022
Toripristone
Zanoterone
Nonsteroidal: Darolutamide
LG-001447
LG-100127
LG-100128
LG-120830
LG-121046
Valproic acid
ZM-150271
ZM-172406
mPR(PAQR)Agonists
5α-Dihydroprogesterone
5β-Dihydroprogesterone
11-Deoxycortisone (21-hydroxyprogesterone)
11-Deoxycortisol (17α,21-dihydroxyprogesterone)
17α-Hydroxyprogesterone
Allopregnanolone
Mifepristone
Pregnenolone
Progesterone
Antagonists
Mifepristone

See also
Receptor/signaling modulators
Progestogens and antiprogestogens
Androgen receptor modulators
Estrogen receptor modulators
List of progestogens

vteXenobiotic-sensing receptor modulatorsCAR
Agonists: 6,7-Dimethylesculetin
Amiodarone
Artemisinin
Benfuracarb
Carbamazepine
Carvedilol
Chlorpromazine
Chrysin
CITCO
Clotrimazole
Cyclophosphamide
Cypermethrin
DHEA (prasterone)
Efavirenz
Ellagic acid
Griseofulvin
Methoxychlor
Mifepristone
Nefazodone
Nevirapine
Nicardipine
Octicizer
Permethrin
Phenobarbital
Phenytoin
Pregnanedione (5β-dihydroprogesterone)
Reserpine
TCPOBOP
Telmisartan
Tolnaftate
Troglitazone
Valproic acid
Antagonists: 3,17β-Estradiol
3α-Androstanol
3α-Androstenol
3β-Androstanol
17-Androstanol
AITC
Ethinylestradiol
Meclizine
Nigramide J
Okadaic acid
PK-11195
S-07662
T-0901317
PXR
Agonists: 17α-Hydroxypregnenolone
17α-Hydroxyprogesterone
Δ4-Androstenedione
Δ5-Androstenediol
Δ5-Androstenedione
AA-861
Allopregnanediol
Allopregnanedione (5α-dihydroprogesterone)
Allopregnanolone (brexanolone)
Alpha-Lipoic acid
Ambrisentan
AMI-193
Amlodipine besylate
Antimycotics
Artemisinin
Aurothioglucose
Bile acids
Bithionol
Bosentan
Bumecaine
Cafestol
Cephaloridine
Cephradine
Chlorpromazine
Ciglitazone
Clindamycin
Clofenvinfos
Chloroxine
Clotrimazole
Colforsin
Corticosterone
Cyclophosphamide
Cyproterone acetate
Demecolcine
Dexamethasone
DHEA (prasterone)
DHEA-S (prasterone sulfate)
Dibunate sodium
Diclazuril
Dicloxacillin
Dimercaprol
Dinaline
Docetaxel
Docusate calcium
Dodecylbenzenesulfonic acid
Dronabinol
Droxidopa
Eburnamonine
Ecopipam
Enzacamene
Epothilone B
Erythromycin
Famprofazone
Febantel
Felodipine
Fenbendazole
Fentanyl
Flucloxacillin
Fluorometholone
Griseofulvin
Guggulsterone
Haloprogin
Hetacillin potassium
Hyperforin
Hypericum perforatum (St John's wort)
Indinavir sulfate
Lasalocid sodium
Levothyroxine
Linolenic acid
LOE-908
Loratadine
Lovastatin
Meclizine
Metacycline
Methylprednisolone
Metyrapone
Mevastatin
Mifepristone
Nafcillin
Nicardipine
Nicotine
Nifedipine
Nilvadipine
Nisoldipine
Norelgestromin
Omeprazole
Orlistat
Oxatomide
Paclitaxel
Phenobarbital
Piperine
Plicamycin
Prednisolone
Pregnanediol
Pregnanedione (5β-dihydroprogesterone)
Pregnanolone
Pregnenolone
Pregnenolone 16α-carbonitrile
Proadifen
Progesterone
Quingestrone
Reserpine
Reverse triiodothyronine
Rifampicin
Rifaximin
Rimexolone
Riodipine
Ritonavir
Simvastatin
Sirolimus
Spironolactone
Spiroxatrine
SR-12813
Suberoylanilide
Sulfisoxazole
Suramin
Tacrolimus
Tenylidone
Terconazole
Testosterone isocaproate
Tetracycline
Thiamylal sodium
Thiothixene
Thonzonium bromide
Tianeptine
Troglitazone
Troleandomycin
Tropanyl 3,5-dimethulbenzoate
Zafirlukast
Zeranol
Antagonists: Ketoconazole
Sesamin

See also
Receptor/signaling modulators

.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;justify-content:center;align-items:baseline}.mw-parser-output .portal-bar-bordered{padding:0 2em;background-color:#fdfdfd;border:1px solid #a2a9b1;clear:both;margin:1em auto 0}.mw-parser-output .portal-bar-unbordered{padding:0 1.7em;margin-left:0}.mw-parser-output .portal-bar-header{margin:0 1em 0 0.5em;padding:0.2em 0;flex:0 0 auto;min-height:24px;line-height:22px}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0 1 auto;padding:0.15em 0;column-gap:1em}.mw-parser-output .portal-bar-item{display:flex;align-items:baseline;margin:0.15em 0;min-height:24px;text-align:left}.mw-parser-output .portal-bar-logo{width:22px;line-height:22px;margin:0 0.2em;text-align:right}.mw-parser-output .portal-bar-link{margin:0 0.2em;text-align:left}@media screen and (max-width:768px){.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;flex-flow:column wrap}.mw-parser-output .portal-bar-header{text-align:center;flex:0;padding-left:0.5em;margin:0 auto}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0;margin:0 auto;column-gap:1em;border-top:1px solid #a2a9b1}}.mw-parser-output .navbox+link+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .navbox+style+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .portal-bar+.navbox-styles+.navbox{margin-top:-1px}Portal:Medicine





